Xenon Pharmaceuticals Inc.
$57.09
▲
0.28%
2026-04-21 10:21:00
www.xenon-pharma.com
NGM: XENE
Explore Xenon Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.48 B
Current Price
$57.09
52W High / Low
$63.95 / $28.19
Stock P/E
—
Book Value
$7.27
Dividend Yield
—
ROCE
-63.09%
ROE
-51.76%
Face Value
—
EPS
$-4.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
358
Beta
0.74
Debt / Equity
1.37
Current Ratio
13.41
Quick Ratio
13.42
Forward P/E
-12.34
Price / Sales
743.06
Enterprise Value
$4.32 B
EV / EBITDA
-11.65
EV / Revenue
575.65
Rating
Strong Buy
Target Price
$79.24
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 2. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 3. | ImmuCell Corporation | $8.02 | — | $72.74 M | — | 4.28% | -3.81% | $8.23 / $4.52 | $2.99 |
| 4. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 5. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 6. | Atrium Therapeutics, Inc. | $14.3 | — | $239.4 M | — | -32.47% | -104.92% | $73.06 / $11.95 | $-4.04 |
| 7. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 7.5 M | 0 M | — |
| Operating Profit | -109.77 M | -96.34 M | -94.23 M | -72.74 M | -77.48 M | — |
| Net Profit | -105.26 M | -90.9 M | -84.71 M | -65.05 M | -65.69 M | — |
| EPS in Rs | -1.1 | -0.95 | -0.89 | -0.68 | -0.69 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.5 M | 0 M | 0 M | 9.43 M |
| Operating Profit | -373.07 M | -279.3 M | -214.05 M | -129.14 M |
| Net Profit | -345.91 M | -234.33 M | -182.39 M | -125.37 M |
| EPS in Rs | -3.62 | -2.46 | -1.91 | -1.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 633.16 M | 798.14 M | 964.8 M | 754.15 M |
| Total Liabilities | 51.4 M | 43.24 M | 36.88 M | 32.65 M |
| Equity | 581.76 M | 754.9 M | 927.92 M | 721.5 M |
| Current Assets | 560.65 M | 635.26 M | 644.96 M | 600.3 M |
| Current Liabilities | 41.79 M | 35.59 M | 27.27 M | 22.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -279.12 M | -181.39 M | -151.11 M | -101.03 M |
| Investing CF | 218 M | 165 M | -111.39 M | -293.4 M |
| Financing CF | 117.11 M | 12.13 M | 353.52 M | 278.47 M |
| Free CF | -279.92 M | -184.46 M | -156.73 M | -103.92 M |
| Capex | -0.8 M | -3.08 M | -5.62 M | -2.89 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -28.48% | -45.48% | — | — |
| Profit Margin % | — | — | -1328.95% | — |
| Operating Margin % | — | — | -1368.91% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -1354.02% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.